USV Launches USEMA - DCGI-Approved Injectable Semaglutide for Type 2 Diabetes
Written By : Dr. Nandita Mohan
Published On 2026-03-21 05:32 GMT | Update On 2026-03-21 05:50 GMT
USV Private Limited, a leading name in diabetes care, has announced the launch of USEMA, its semaglutide injection, for the management of Type 2 Diabetes Mellitus in India. With diabetes prevalence rising rapidly across the country, particularly among individuals with overweight and obesity, the introduction of USEMA aims to address a critical and growing healthcare need.
USEMA is available in two pen formats: a 2 mg pen delivering 0.25 mg and 0.5 mg doses, and a 4 mg pen delivering a 1 mg dose, offering flexibility in treatment based on patient requirements. Manufactured in India under stringent global quality standards, the product demonstrates proven bioequivalence, with similar efficacy, safety, and immunogenicity profiles as the reference innovator.
Developed through an integrated manufacturing process—from active pharmaceutical ingredient (API) to finished formulation—USEMA ensures consistency in quality, supported by robust cold-chain management.
Beyond treatment, USEMA is supported by a comprehensive patient care program designed to guide individuals through every stage of their diabetes journey. This initiative focuses on improving adherence, outcomes, and long-term health milestones.
With over six decades of experience, USV continues to strengthen its commitment to advancing diabetes care in India through innovation and patient-centric solutions.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.